Current staging systems for pancreatic cancer

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 539-549

  Appel, Betsy L ^a   Tolat, Parag ^a   Evans, Douglas B ^a   Tsai, Susan ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Pancreatic cancer; resectability; staging

Indexed keywords

CA 19-9 ANTIGEN;

ASCITES FLUID CYTOLOGY; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; META ANALYSIS (TOPIC); METASTASIS; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; THERAPY EFFECT;

HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84871198714     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318278c5b5     Document Type: Review

References (67)

1. Friess H, Kleeff J, Silva JC, et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg. 1998;186: 675-682.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemci-tabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297: 267-277.
3. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of che-moradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
4. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120:899-903.
5. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma, version 2.2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/ pancreatic.pdf. Accessed November 15, 2012.
6. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospec-tively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503-3510.
7. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Data Base. Cancer. 2007;110:738-744.
8. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935-949; discussion 949-950.
9. Poon RT, Fan ST, Lo CM, et al. Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement. World J Surg. 2004;28:602-608.
10. Riediger H, Makowiec F, Fischer E, et al. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg. 2006;10: 1106-1115.
11. Shibata C, Kobari M, Tsuchiya T, et al. Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas. World J Surg. 2001;25:1002-1005.
12. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 Patients. Ann Surg. 1995;221: 721-731; discussion 723-731.
13. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg. 1996;224:342-347; discussion 347-349.
14. Evans DB, Farnell MB, Lillemoe KD, et al. Surgical treatment of re-sectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1736-1744.
15. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-846; discussion 838-846.
16. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168: 1439-1443.
17. Lee JK, Kim AY, Kim PN, et al. Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR an-giography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma. Eur J Radiol. 2010;73:310-316.
18. Tamm EP, Loyer EM, Faria S, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. 2006;31:568-574.
19. Hunt GC, Faigel DO. Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc. 2002;55:232-237.
20. Krishna NB, Mehra M, Reddy AV, et al. EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. Gastrointest Endosc. 2009;70:70-79.
21. Puli SR, Singh S, Hagedorn CH, et al. Diagnostic accuracy of EUS for vascular invasion in pancreatic and periampullary cancers: a meta-analysis and systematic review. Gastrointest Endosc. 2007;65: 788-797.
22. Kinney TP, Lai R, Freeman ML. Endoscopic approach to acute pancreatitis. Rev Gastroenterol Disord. 2006;6:119-135.
23. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcita-bine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3487-3495.
24. Ross WA, Wasan SM, Evans DB, et al. Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. Gastrointest Endosc. 2008;68:461-466.
25. Mullen JT, Lee JH, Gomez HF, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg. 2005;9: 1094-1104; discussion 1095-1104.
26. Aadam AA, Evans DB, Khan A, et al. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc. 2012;76:67-75.
27. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979; 5:957-971.
28. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adeno-carcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012; 3:105-119.
29. Barton JG, Bois JP, Sarr MG, et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13:2050-2058.
30. Hata S, Sakamoto Y, Yamamoto Y, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19:636-641.
31. Lundin J, Roberts PJ, Kuusela P, et al. The prognostic value of preoper-ative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-519.
32. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37:269-274.
33. Katz MH, Varadhachary GR, Fleming JB, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794-1801.
34. Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peri-pancreatic malignancy. Ann Surg. 1996;223:134-140.
35. Jimenez RE, Warshaw AL, Rattner DW, et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135: 409-414; discussion 405-414.
36. Hariharan D, Constantinides VA, Froeling FE, et al. The role of lapa-roscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancersVa meta-analysis. Eur J Surg Oncol. 2010; 36:941-948.
37. Satoi S, Yanagimoto H, Toyokawa H, et al. Selective use of staging lap-aroscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resect-able pancreatic cancer. Pancreas. 2011;40:426-432.
38. Liu RC, Traverso LW. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc. 2005;19:638-642.
39. Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg. 1991;161:26-29; discussion 29-30.
40. Jimenez RE, Warshaw AL, FernandezYdel Castillo C. Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000;7:15-20.
41. Winter JM, Cameron JL, Campbell KA, et al. 1423 Pancreaticoduo- denectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-1210; discussion 1191-1210.
42. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52-60.
43. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multi-disciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836-847.
44. Fatima J, Schnelldorfer T, Barton J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145:167-172.
45. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758-768.
46. Hernandez J, Mullinax J, Clark W, et al. Survival after pancreaticoduo-denectomy is not improved by extending resections to achieve negative margins. Ann Surg. 2009;250:76-80.
47. House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11:1549-1555.
48. Hattangadi JA, Hong TS, Yeap BY, et al. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer. 2009;115:3640-3650.
49. Chatterjee D, Katz MH, Rashid A, et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012;36:409-417.
50. Chatterjee D, Rashid A, Wang H, et al. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adeno-carcinoma who have received neoadjuvant therapy and pancreaticoduo-denectomy. Am J Surg Pathol. 2012;36:552-559.
51. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141:610-618.
52. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol. 2006;13:1189-1200.
53. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pan-createctomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165-174.
54. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007; 142:767-723; discussion 764-773.
55. Hellan M, Sun CL, Artinyan A, et al. The impact of lymph node number on survival in patients with lymph nodeYnegative pancreatic cancer. Pancreas. 2008;37:19-24.
56. Showalter TN, Winter KA, Berger AC, et al. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys. 2011;81:1328-1335.
57. Huebner M, Kendrick M, Reid-Lombardo KM, et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarci-noma. J Gastrointest Surg. 2012;16:920-926.
58. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymph-adenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355-366; discussion 358-366.
59. Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymph-adenectomy for periampullary adenocarcinomaVpart 3: update on 5-year survival. J Gastrointest Surg. 2005;9:1191-1204; discussion 1196-1204.
60. Rupp CC, Linehan DC. Extended lymphadenectomy in the surgery of pancreatic adenocarcinoma and its relation to quality improvement issues. J Surg Oncol. 2009;99:207-214.
61. Henne-Bruns D, Vogel I, Luttges J, et al. Surgery for ductal adenocarci-noma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg. 2000;24: 595-601; discussion 592-601.
62. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337-1344.
63. Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 2012;136:100-109.
64. Ishikawa O, Ohhigashi H, Teshima T, et al. Clinical and histopathologic appraisal of preoperative irradiation for adenocarcinoma of the pancrea-ticoduodenal region. J Surg Oncol. 1989;40:143-151.
65. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-1339.
66. White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214-221.
67. Zhao Q, Rashid A, Gong Y, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarci-noma is associated with a better prognosis. Ann Diagn Pathol. 2012; 16:29-37.